Elucidation of thioredoxin as a molecular target for antitumor quinols

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3911-3919

  Bradshaw, Tracey D ^a   Matthews, Charles S ^a   Cookson, Jennifer ^a   Chew, Eng Hui ^a   Shah, Manish ^a   Bailey, Kevin ^a   Monks, Anne ^b   Harris, Erik ^b   Westwell, Andrew D ^a   Wells, Geoffrey ^a   Laughton, Charles A ^a   Stevens, Malcolm F G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 BENZENESULFONYL 1H INDOL 2 YL) 4 HYDROXYCYCLOHEXA 2,5 DIENONE; 4 (BENZOTHIAZOL 2 YL) 4 HYDROXYCYCLOHEXA 2,5 DIENONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; CYSTEINE; INSULIN; QUINOL DERIVATIVE; SULFUR; THIOREDOXIN; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOLECULAR MODEL; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 20944439854     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4141     Document Type: Article

References (25)

1. Wells G, Berry JM, Bradshaw TD, et al. 4-Substituted 4-hydroxycyclohexa- 2.5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem 2003;46:532-41.
2. Berry JM, Bradshaw TD, Fichtner I, et al. Quinols as novel therapeutic agents. 2. 4-((1-Arylsulfonyl)indole-2-ul)-4-hydroxycyclohexa-2,5-dien-1ones and related agents as potent and selective antitumor agents. J Med Chem 2005;48:639-44.
3. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel Res 1995;34:91-109.
4. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow-cytometry. J Immunol Methods 1991;139:271-9.
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
6. Kunkel MW, Kirkpatrick DL, Johnson JI, Powis G. Cell line-directed screening assay for inhibitors of thioredoxin reductase signalling as potential anti-cancer drugs. Anti-cancer drug Des 1997;12:659-70.
7. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
8. Pallis M, Bradshaw TD, Westwell AD, Grundy M, Stevens MFG, Russell N. Induction of apoptosis without redox catastrophe by thioredoxin-inhibitory compounds. Biochem Pharmacol 2003;66:1695-705.
9. Westwell AD, Berry JM, Bradshaw TD, et al. Phenolic oxidation products as novel antitumour agents. Clin Cancer Res 2003;9:6205S.
10. Watson WH, Yang XM, Choi YE, Jones DP, Kehrer JP. Thioredoxin and its role in toxicology. Toxicol Sci 2004;78:3-14.
11. Masutani H, Yodoi J. Thioredoxin overview. Methods Enzymol 2002;347:279-86.
12. Gromer S, Urig S, Becker K. The thioredoxin system: from science to clinic. Med Res Rev 2004;24:40-89.
13. Hodges NJ, Smart D, Lee AJ, Lewis NA, Chipman JK. Activation of c-jun-N-terminal kinase in A549 lung carcinoma cells by sodium dichromate: role of dissociation of apoptosis signal regulating kinase-1 from its physiological inhibitor thioredoxin. Toxicology 2004;197:101-12.
14. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001;30:421-55.
15. Raffel J, Bhattacharyya AK, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2003;142:46-51.
16. Mukherjee A, Bradshaw TD, Westwell AD, Stevens MFG, Carmichael J, Martin SG. Characterising the anti-tumour and anti-angiogenic activity of AW 464 (NSC 706704), a novel thioredoxin inhibitor. Brit J Cancer 2005;92:350-8.
17. Hisada T, Salmon M, Nasuhara Y, Chung KF. Involvement of haemoxygenase-1 in ozone-induced airway inflammation and hyperresponsiveness. Eur J Pharmacol 2000;399:229-34.
18. Sullivan DC, Huminiecki L, Moore JW, et al. EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem 2003;278:47079-88.
19. 2/M cell-cycle progression and cellular senescence. Nat Cell Biol 2004;6:215-26.
20. Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 1997;94:3633-8.
21. Jin S, Antinore MJ, Lung F-DT, et al. The GADD45 inhibition of cdc2 kinase correlates with GADD45-mediated growth suppression. J Biol Chem 2000;275:16602-8.
22. Jiang H, Yang L-Y. Cell cycle abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision. Cancer Res 1999;59:4529-34.
23. Bunch RT, Eastman A. 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 1997;8:779-88.
24. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001;61:5843-9.
25. Kirkpatrick DL, Kuperus M, Dowdeswell M, et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 1998;55:987-94.